查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1598714

2 型糖尿病药物市场：按药物、应用和分布分类 - 全球预测 2025-2030

Type 2 Diabetes Drugs Market by Drug (Injectables, Oral), Application (Cardiovascular Safety, Glycemic Control, Hypoglycemia Avoidance), Distribution - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年2型糖尿病药物市值为711.7亿美元，预计到2024年将达到770.7亿美元，复合年增长率为8.81%，到2030年将达到1285.5亿美元。

2 型糖尿病药物市场包括透过调节血糖值来控制和治疗 2 型糖尿病的药物。这些药物包括不同类型的药物，如Metformin、磺酰尿素类、噻唑烷类、DPP-4抑制剂、GLP-1受体促效剂和SGLT2抑制剂。 2 型糖尿病盛行率不断上升、人口老化以及糖尿病管理意识不断增强，推动了该市场的发展。预防心血管疾病、神经病变和视力障碍等併发症的需求强调了对这些药物的需求。儘管主要用于门诊环境，但人们对个人化医疗和远端医疗选择也越来越感兴趣。最终用途范围集中在医院、诊所和居家医疗。关键的成长要素包括给药系统的创新、医疗保健支出的增加和保险覆盖范围的扩大。特别值得注意的是，使用人工智慧和机器学习来客製化治疗计划的机会不断增加。公司可以透过与高科技公司建立伙伴关係来利用这一点。然而，挑战仍然存在，例如严格的监管要求和副作用，这些都阻碍了采用。学名药降低了利润率，也阻碍了市场成长。创新领域包括口服胰岛素製剂、长效注射剂和针对β细胞功能障碍的药物。基因疗法和基于微生物的治疗是开拓的研究途径，可能会重新定义糖尿病管理。整体而言，市场竞争激烈，需要大量研发投资来维持创新。能够透过新颖的治疗方法满足未满足的需求，同时确保负担能力和易用性的公司可能会在这个动态环境中占据优势。透过利用资料分析获得患者洞察并整合数位健康工具，您可以进一步巩固您的市场地位。

主要市场统计
基准年[2023] 711.7亿美元
预测年份 [2024] 770.7亿美元
预测年份 [2030] 1285.5亿美元
复合年增长率（%） 8.81%

市场动态：快速发展的 2 型糖尿病药物市场的关键市场洞察

2 型糖尿病药物市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 全球糖尿病盛行率的重要性
    • 由于不健康的饮食和久坐的生活方式，肥胖人口不断增加
    • 政府提高健康意识的措施和计划
  • 市场限制因素
    • 影响品牌声誉的产品召回
  • 市场机会
    • 製药商在糖尿病治疗方面的进展
    • 增加研发和医疗基础建设的投资
  • 市场挑战
    • 严格的法规环境和漫长的核准流程

波特五力：驾驭第 2 型糖尿病药物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势、解决弱点并避免潜在的挑战，以确保更强大的市场地位。

PESTLE分析：了解外部对第 2 型糖尿病药物市场的影响

外部宏观环境因素在塑造第 2 型糖尿病治疗药物市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助企业预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解第二型糖尿病治疗药物市场的竞争状况

对第 2 型糖尿病治疗药物市场的详细市场占有率分析可以对供应商的业绩进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 2 型糖尿病药物市场定位矩阵供应商绩效评估

FPNV 定位矩阵是评估第 2 型糖尿病药物市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，规划 2 型糖尿病药物市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对 2 型糖尿病治疗药物市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 世界性糖尿病盛行率的重要性
      • 由于不健康的饮食和久坐的生活方式，肥胖人数不断增加
      • 政府提高健康意识的措施和计划
    • 抑制因素
      • 产品回忆影响品牌声誉
    • 机会
      • 製药商在糖尿病治疗方面的进展
      • 增加研发和医疗基础建设的投资
    • 任务
      • 严格的法规环境和漫长的核准流程
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章 2 型糖尿病药物市场（依药物）

  • 注射
    • Aspart
    • Exenatide
    • 甘精胰岛素
    • 胰岛素
    • 来拉鲁肽
    • 普拉姆林潮汐
  • 口服
    • α葡萄Glucosidase抑制剂
    • 双胍
    • Dipeptidyl Peptidase-4抑制剂
    • 类升糖素
    • 促效剂
    • 分泌刺激剂
    • 钠葡萄糖共同输送体2抑制剂
    • 磺酰尿素类
    • 胰岛素增敏剂

第七章 2 型糖尿病药物市场：依应用分类

  • 心血管安全
  • 血糖控制
  • 避免低血糖

第八章 2型糖尿病药物市场经销商

  • 医院药房
  • 网路药房
  • 零售药房

第九章北美及南美第二型糖尿病药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太第二型糖尿病药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲第2型糖尿病药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • Amgen Inc.
  • AstraZeneca
  • Bayer Inc
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Chugai Pharmaceutical Co., Ltd.
  • DAIICHI SANKYO COMPANY, LIMITED
  • Eli Lilly and Company
  • GSK plc
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Peptron
  • Pfizer Inc.
  • Sanofi Group
Product Code: MRR-7162E4C3E9C3

The Type 2 Diabetes Drugs Market was valued at USD 71.17 billion in 2023, expected to reach USD 77.07 billion in 2024, and is projected to grow at a CAGR of 8.81%, to USD 128.55 billion by 2030.

The Type 2 Diabetes Drugs market encompasses medications that are designed to manage and treat type 2 diabetes by regulating blood sugar levels. These drugs include a variety of treatment types such as metformin, sulfonylureas, thiazolidinediones, DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT2 inhibitors. The market is driven by the growing prevalence of type 2 diabetes, aging populations, and increased awareness of diabetes management. The necessity of these drugs is underscored by the need to prevent complications like cardiovascular disease, neuropathy, and vision problems. Application primarily involves outpatient settings, though there is rising interest in personalized medicine and telehealth options for delivery. End-use scope focuses on hospitals, clinics, and homecare settings. Key growth factors include innovations in drug delivery systems, rising healthcare expenditure, and expanded insurance coverage, which enhance product accessibility. Notably, there's a burgeoning opportunity in the use of artificial intelligence and machine learning to tailor treatment plans. Companies can leverage partnerships with tech firms to capitalize on this. However, challenges remain, such as stringent regulatory requirements and side effect profiles of these drugs, which can deter adoption. Market growth is also hampered by generic drugs, which curtail profit margins. Innovation areas include the development of oral insulin, longer-duration injectables, and drugs targeting beta-cell dysfunction. Gene therapy and microbiome-based therapies represent untapped research avenues that might redefine diabetes management. Overall, the nature of the market is highly competitive with significant R&D investment required to sustain innovation. Companies that can address unmet needs with novel therapeutic agents while ensuring affordability and ease-of-use will likely excel in this dynamic environment. Utilizing data analytics for patient insights and integrating digital health tools can further strengthen market positions.

KEY MARKET STATISTICS
Base Year [2023] USD 71.17 billion
Estimated Year [2024] USD 77.07 billion
Forecast Year [2030] USD 128.55 billion
CAGR (%) 8.81%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Type 2 Diabetes Drugs Market

The Type 2 Diabetes Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Significance of diabetic prevalence globally
    • Rise in obesity population coupled with unhealthy diets and sedentary lifestyles
    • Government initiatives and programs to create health awareness
  • Market Restraints
    • Products recall affecting brand reputation
  • Market Opportunities
    • Advancements in diabetic medications by pharmaceutical manufacturers
    • Rising investment in R&D and healthcare infrastructure development
  • Market Challenges
    • Stringent regulatory environment and time-consuming approval process

Porter's Five Forces: A Strategic Tool for Navigating the Type 2 Diabetes Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Type 2 Diabetes Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Type 2 Diabetes Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Type 2 Diabetes Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Type 2 Diabetes Drugs Market

A detailed market share analysis in the Type 2 Diabetes Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Type 2 Diabetes Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Type 2 Diabetes Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Type 2 Diabetes Drugs Market

A strategic analysis of the Type 2 Diabetes Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Type 2 Diabetes Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Amgen Inc., AstraZeneca, Bayer Inc, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Chugai Pharmaceutical Co., Ltd., DAIICHI SANKYO COMPANY, LIMITED, Eli Lilly and Company, GSK plc, Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Peptron, Pfizer Inc., and Sanofi Group.

Market Segmentation & Coverage

This research report categorizes the Type 2 Diabetes Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug, market is studied across Injectables and Oral. The Injectables is further studied across Aspart, Exenatide, Glargine, Insulin, Leraglutide, and Pramlintide. The Oral is further studied across Alpha-Glucosidase Inhibitors, Biguanides, Dipeptidyl Peptidase-4 Inhibitors, Glucagon-Like Peptide, Receptor Agonists, Secretagogues, Sodium Glucose Cotransport 2 Inhibitors, Sulfonylureas, and Thiazolidinediones.
  • Based on Application, market is studied across Cardiovascular Safety, Glycemic Control, and Hypoglycemia Avoidance.
  • Based on Distribution, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Significance of diabetic prevalence globally
      • 5.1.1.2. Rise in obesity population coupled with unhealthy diets and sedentary lifestyles
      • 5.1.1.3. Government initiatives and programs to create health awareness
    • 5.1.2. Restraints
      • 5.1.2.1. Products recall affecting brand reputation
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in diabetic medications by pharmaceutical manufacturers
      • 5.1.3.2. Rising investment in R&D and healthcare infrastructure development
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory environment and time-consuming approval process
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Type 2 Diabetes Drugs Market, by Drug

  • 6.1. Introduction
  • 6.2. Injectables
    • 6.2.1. Aspart
    • 6.2.2. Exenatide
    • 6.2.3. Glargine
    • 6.2.4. Insulin
    • 6.2.5. Leraglutide
    • 6.2.6. Pramlintide
  • 6.3. Oral
    • 6.3.1. Alpha-Glucosidase Inhibitors
    • 6.3.2. Biguanides
    • 6.3.3. Dipeptidyl Peptidase-4 Inhibitors
    • 6.3.4. Glucagon-Like Peptide
    • 6.3.5. Receptor Agonists
    • 6.3.6. Secretagogues
    • 6.3.7. Sodium Glucose Cotransport 2 Inhibitors
    • 6.3.8. Sulfonylureas
    • 6.3.9. Thiazolidinediones

7. Type 2 Diabetes Drugs Market, by Application

  • 7.1. Introduction
  • 7.2. Cardiovascular Safety
  • 7.3. Glycemic Control
  • 7.4. Hypoglycemia Avoidance

8. Type 2 Diabetes Drugs Market, by Distribution

  • 8.1. Introduction
  • 8.2. Hospital Pharmacies
  • 8.3. Online Pharmacies
  • 8.4. Retail Pharmacies

9. Americas Type 2 Diabetes Drugs Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Type 2 Diabetes Drugs Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Type 2 Diabetes Drugs Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Amgen Inc.
  • 3. AstraZeneca
  • 4. Bayer Inc
  • 5. Boehringer Ingelheim International GmbH
  • 6. Bristol-Myers Squibb Company
  • 7. Chugai Pharmaceutical Co., Ltd.
  • 8. DAIICHI SANKYO COMPANY, LIMITED
  • 9. Eli Lilly and Company
  • 10. GSK plc
  • 11. Johnson & Johnson Services, Inc.
  • 12. Merck & Co., Inc.
  • 13. Novartis AG
  • 14. Peptron
  • 15. Pfizer Inc.
  • 16. Sanofi Group

LIST OF FIGURES

  • FIGURE 1. TYPE 2 DIABETES DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. TYPE 2 DIABETES DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. TYPE 2 DIABETES DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. TYPE 2 DIABETES DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. TYPE 2 DIABETES DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. TYPE 2 DIABETES DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ASPART, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY EXENATIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLARGINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INSULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY LERAGLUTIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRAMLINTIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ALPHA-GLUCOSIDASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BIGUANIDES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DIPEPTIDYL PEPTIDASE-4 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLUCAGON-LIKE PEPTIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY RECEPTOR AGONISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SECRETAGOGUES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORT 2 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SULFONYLUREAS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY THIAZOLIDINEDIONES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY CARDIOVASCULAR SAFETY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLYCEMIC CONTROL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY HYPOGLYCEMIA AVOIDANCE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 49. BRAZIL TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 52. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 53. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 54. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 57. MEXICO TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 58. MEXICO TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 59. MEXICO TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. MEXICO TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 63. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 64. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 66. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 73. AUSTRALIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 74. AUSTRALIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 75. AUSTRALIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 76. AUSTRALIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. AUSTRALIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 78. CHINA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 79. CHINA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 80. CHINA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 81. CHINA TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. CHINA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 83. INDIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 84. INDIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 85. INDIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 86. INDIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. INDIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 88. INDONESIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 89. INDONESIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 90. INDONESIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 91. INDONESIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. INDONESIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 93. JAPAN TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 94. JAPAN TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 95. JAPAN TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 96. JAPAN TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. JAPAN TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 98. MALAYSIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 99. MALAYSIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 100. MALAYSIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 101. MALAYSIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. MALAYSIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 103. PHILIPPINES TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 104. PHILIPPINES TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 105. PHILIPPINES TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 106. PHILIPPINES TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 107. PHILIPPINES TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 108. SINGAPORE TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 109. SINGAPORE TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 110. SINGAPORE TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 111. SINGAPORE TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 112. SINGAPORE TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 113. SOUTH KOREA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 114. SOUTH KOREA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 115. SOUTH KOREA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 116. SOUTH KOREA TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. SOUTH KOREA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 118. TAIWAN TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 119. TAIWAN TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 120. TAIWAN TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 121. TAIWAN TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 122. TAIWAN TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 123. THAILAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 124. THAILAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 125. THAILAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 126. THAILAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 127. THAILAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 128. VIETNAM TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 129. VIETNAM TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 130. VIETNAM TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 131. VIETNAM TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. VIETNAM TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 139. DENMARK TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 140. DENMARK TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 141. DENMARK TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 142. DENMARK TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 143. DENMARK TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 144. EGYPT TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 145. EGYPT TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 146. EGYPT TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 147. EGYPT TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 148. EGYPT TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 149. FINLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 150. FINLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 151. FINLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 152. FINLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 153. FINLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 154. FRANCE TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 155. FRANCE TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 156. FRANCE TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 157. FRANCE TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 158. FRANCE TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 159. GERMANY TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 160. GERMANY TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 161. GERMANY TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 162. GERMANY TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 163. GERMANY TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 164. ISRAEL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 165. ISRAEL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 166. ISRAEL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 167. ISRAEL TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 168. ISRAEL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 169. ITALY TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 170. ITALY TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 171. ITALY TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 172. ITALY TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 173. ITALY TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 174. NETHERLANDS TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 175. NETHERLANDS TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 176. NETHERLANDS TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 177. NETHERLANDS TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 178. NETHERLANDS TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 179. NIGERIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 180. NIGERIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 181. NIGERIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 182. NIGERIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 183. NIGERIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 184. NORWAY TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 185. NORWAY TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 186. NORWAY TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 187. NORWAY TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 188. NORWAY TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 189. POLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 190. POLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 191. POLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 192. POLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 193. POLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 194. QATAR TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 195. QATAR TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 196. QATAR TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 197. QATAR TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 198. QATAR TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 199. RUSSIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 200. RUSSIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 201. RUSSIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 202. RUSSIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 203. RUSSIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 204. SAUDI ARABIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 205. SAUDI ARABIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 206. SAUDI ARABIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 207. SAUDI ARABIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 208. SAUDI ARABIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 209. SOUTH AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 210. SOUTH AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 211. SOUTH AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 212. SOUTH AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 213. SOUTH AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 214. SPAIN TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 215. SPAIN TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 216. SPAIN TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 217. SPAIN TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 218. SPAIN TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 219. SWEDEN TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 220. SWEDEN TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 221. SWEDEN TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 222. SWEDEN TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 223. SWEDEN TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 224. SWITZERLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 225. SWITZERLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 226. SWITZERLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 227. SWITZERLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 228. SWITZERLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 229. TURKEY TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 230. TURKEY TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 231. TURKEY TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 232. TURKEY TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 233. TURKEY TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED ARAB EMIRATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED ARAB EMIRATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED ARAB EMIRATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED ARAB EMIRATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 238. UNITED ARAB EMIRATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 239. UNITED KINGDOM TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 240. UNITED KINGDOM TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 241. UNITED KINGDOM TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 242. UNITED KINGDOM TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 243. UNITED KINGDOM TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 244. TYPE 2 DIABETES DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 245. TYPE 2 DIABETES DRUGS MARKET, FPNV POSITIONING MATRIX, 2023